ライフサイエンスコーパス: adverse cardiovascular event

1 ts (a composite of major bleeding or a major adverse cardiovascular event).

2 ilure exacerbation was the most common major adverse cardiovascular event.

3 magnetic resonance imaging (MRI) to predict adverse cardiovascular events.

4 d is associated with increased mortality and adverse cardiovascular events.

5 The primary outcome was major adverse cardiovascular events.

6 etabolic syndrome (MetS) doubles the risk of adverse cardiovascular events.

7 d with minimally elevated troponin and major adverse cardiovascular events.

8 patient survival and the occurrence of major adverse cardiovascular events.

9 f IPST was strongly predictive of subsequent adverse cardiovascular events.

10 s, it could help explain the morning peak in adverse cardiovascular events.

11 ced inhibition have increased risk for major adverse cardiovascular events.

12 ne was associated with a lower risk of major adverse cardiovascular events.

13 se patients may increase their risk of major adverse cardiovascular events.

14 5) 6-month restenosis; and (6) 6-month major adverse cardiovascular events.

15 leles for CYP2C19 have an increased risk for adverse cardiovascular events.

16 tic atherosclerosis are predictive of future adverse cardiovascular events.

17 ted with an increased risk of incident major adverse cardiovascular events.

18 ivity with its known increased risk of major adverse cardiovascular events.

19 related particles (TRPs) are associated with adverse cardiovascular events.

20 non and prothrombotic state leading to major adverse cardiovascular events.

21 ferences in procedure success rates or major adverse cardiovascular events.

22 of AVC is associated with increased risk of adverse cardiovascular events.

23 was promptly removed from the market due to adverse cardiovascular events.

24 ce that clopidogrel-drug interactions impact adverse cardiovascular events.

25 size and was associated with higher rates of adverse cardiovascular events.

26 underlie the well-documented morning peak in adverse cardiovascular events.

27 rtension potentially increasing the risk for adverse cardiovascular events.

28 eases the risk of cardiovascular disease and adverse cardiovascular events.

29 n was found between OT and the risk of major adverse cardiovascular events.

30 d risk of peripheral edema, weight gain, and adverse cardiovascular events.

31 ially contribute to the day/night pattern of adverse cardiovascular events.

32 eir soluble levels have been associated with adverse cardiovascular events.

33 igher rates of in-hospital and 9-month major adverse cardiovascular events.

34 Secondary outcomes included major adverse cardiovascular events.

35 d serious infections, malignancies, or major adverse cardiovascular events.

36 red EPD use in all-cause mortality and major adverse cardiovascular events.

37 f sex, CFR, and angiographic CAD severity on adverse cardiovascular events.

38 t PCI were primary outcomes comprising major adverse cardiovascular events.

39 heart rate has been unequivocally linked to adverse cardiovascular events.

40 onfatal), all-cause death, and other serious adverse cardiovascular events.

41 ortality (HR 0.53 [95% CI 0.40-0.71]), major adverse cardiovascular events (0.78 [0.69-0.87]), and ho

42 ears; HR, 0.57; 95% CI, 0.50-0.65) and major adverse cardiovascular events (2.31 versus 3.45 events p

43 Study outcomes included in-hospital major adverse cardiovascular events, 30-day mortality, and 1-y

44 isease have lower rates of in-hospital major adverse cardiovascular events, 30-day mortality, and 1-y

45 per patient; hospital utilization; and major adverse cardiovascular events, 30-day mortality, bleedin

46 etes mellitus were at greater risk for major adverse cardiovascular events (32% versus 11%; P<0.001)

47 s (85% versus 94%; P<0.001) and higher major adverse cardiovascular events (4.3% versus 1.1%; P<0.001

48 e no significant differences in 30-day major adverse cardiovascular events (4.8% versus 5.4%, P=0.73;

49 ality (24.6% vs. 5.4%, p < 0.0001) and major adverse cardiovascular events (40.3% vs. 20.5%, p < 0.00

50 din and heparin were the occurrence of major adverse cardiovascular events (a composite of death, myo

51 udied on 30-day mortality, in-hospital major adverse cardiovascular events (a composite of in-hospita

52 therapy was associated with increased major adverse cardiovascular event (adjusted hazard ratio, 1.4

53 O level predicted an increased risk of major adverse cardiovascular events after adjustment for tradi

54 al arterial disease (PAD) have high rates of adverse cardiovascular events after percutaneous coronar

55 events, defined as the combination of major adverse cardiovascular events (all-cause mortality, myoc

56 Major adverse cardiovascular event alone was also not signific

57 Secondary endpoints were major adverse cardiovascular events alone, all-cause mortality

58 posite secondary end point of ischemic major adverse cardiovascular events also did not differ betwee

59 Adverse cardiovascular events among patients with normal

60 d point, the risk for the composite of major adverse cardiovascular events among the groups was simil

61 al injection with ixmyelocel-T reduces major adverse cardiovascular event and improves symptoms in pa

62 parathyroid hormone levels raise the risk of adverse cardiovascular events and atraumatic bone fractu

63 Major adverse cardiovascular events and bleeding within 6 mont

64 ndary end points included the rates of major adverse cardiovascular events and definite stent thrombo

65 ry end points included 30-day rates of major adverse cardiovascular events and Global Utilization of

66 uently reported a reduction in 3-point major adverse cardiovascular events and HF hospitalization ris

67 hospitalization for heart failure, and major adverse cardiovascular events and higher risk of below-k

68 Our coprimary outcomes were major adverse cardiovascular events and home time (days alive

69 ntricular (LV) remodeling is associated with adverse cardiovascular events and is frequently observed

70 ding complications and their impact on major adverse cardiovascular events and mortality outcomes.

71 The secondary end points were major adverse cardiovascular events and mortality.

72 cell (RBC) transfusions are associated with adverse cardiovascular events and multiorgan injury.

73 rapy was associated with lower risk of major adverse cardiovascular events and nearly 1 month more ho

74 acute coronary syndrome, the rates of major adverse cardiovascular events and net adverse clinical e

75 yceride levels are associated with a risk of adverse cardiovascular events and pancreatitis.

76 PHOENIX, cangrelor reduced the odds of major adverse cardiovascular events and stent thrombosis in wo

77 a significant independent predictor of major adverse cardiovascular events and target vessel revascul

78 ints, 1.70 (1.27 to 2.27; P<0.001) for major adverse cardiovascular events, and 1.36 (1.04 to 1.79; P

79 t study to analyze long-term survival, major adverse cardiovascular events, and factors associated wi

80 ce of VHD increased the risk of death, major adverse cardiovascular events, and major bleeding but di

81 cess, radial access reduces mortality, major adverse cardiovascular events, and major bleeding in pat

82 cross-over to another arterial access, major adverse cardiovascular events, and major vascular events

83 clinical risk factors and bleeding episodes, adverse cardiovascular events, and mortality.

84 ation, and the composite end points of major adverse cardiovascular events, and net adverse clinical

85 ; and 3) reported all-cause mortality, major adverse cardiovascular events, and other outcomes of int

86 Many patients at high risk for adverse cardiovascular events are unable to achieve the

87 al injury have a similar crude rate of major adverse cardiovascular events as those with type 1 myoca

88 The secondary end points included major adverse cardiovascular events as well as changes in left

89 r stenoses significantly reduced the risk of adverse cardiovascular events, as compared with PCI limi

90 Efficacy outcomes were major adverse cardiovascular events, as well as death, cardiov

91 th at modifying broad risk factors for major adverse cardiovascular events, as well as reducing limb-

92 ment was previously limited due to increased adverse cardiovascular events associated with rapid rele

93 shortened bleeding time, and, possibly, the adverse cardiovascular events associated with rofecoxib.

94 of subsequent all-cause mortality and major adverse cardiovascular events at 1 year after discharge,

95 similar by sex, the cumulative rate of major adverse cardiovascular events at 1 year was higher in yo

96 for cessation, and associated risk of major adverse cardiovascular events at 1 year.

97 scharge from the emergency department, major adverse cardiovascular events at 28 days, and cumulative

98 omes and no significant differences in major adverse cardiovascular events at 28 days.

99 We produced Kaplan-Meier estimates of major adverse cardiovascular events at 3 years by intention to

100 The end point was major adverse cardiovascular events at 3 years, defined as the

101 nterval [CI]: 0.48 to 1.23; p = 0.27) or net adverse cardiovascular events at 30 days (14.4% vs. 16.1

102 Rates of major adverse cardiovascular events at 48 h were not significa

103 The rate of major adverse cardiovascular events at 5 years was 31.0% in th

104 inical end point was the occurrence of major adverse cardiovascular events at long-term follow-up.

105 ardial injury and an increased risk of major adverse cardiovascular events at long-term follow-up.

106 n was associated with similar rates of major adverse cardiovascular events, but a greater risk of min

107 atory bowel disease (IBD) has been linked to adverse cardiovascular events, but a relation to heart f

108 e, acarbose did not reduce the risk of major adverse cardiovascular events, but did reduce the incide

109 salicylic acid) prophylaxis suppresses major adverse cardiovascular events, but its rapid turnover li

110 ary heart disease by 27% (P=0.002) and major adverse cardiovascular events by 25% (P=0.004) consisten

111 ary heart disease by 27% (P=0.033) and major adverse cardiovascular events by 25% (P=0.037) during th

112 tigated were cardiovascular mortality, major adverse cardiovascular events (cardiovascular mortality,

113 s in this class can reduce three-point major adverse cardiovascular events, cardiovascular mortality,

114 the effects of canakinumab on rates of major adverse cardiovascular events, cardiovascular mortality,

115 ban alone did not significantly reduce major adverse cardiovascular events compared with asprin alone

116 a 2.5- and 4.1-fold increased risk of major adverse cardiovascular events compared with patients who

117 f-label use associated with increased 30-day adverse cardiovascular events compared with the lowest t

118 (8.8%) patients with radial access had major adverse cardiovascular events, compared with 429 (10.3%)

119 on; the secondary outcome was ischemic major adverse cardiovascular events (composite of CAD death, n

120 ation use at discharge, mortality, and major adverse cardiovascular events (composite of death, reinf

121 Subsequent major adverse cardiovascular events (death from cardiac causes

122 In a post hoc analysis, the rate of major adverse cardiovascular events (death from coronary heart

123 l coronary artery disease, the rate of major adverse cardiovascular events (death, MI, or stroke) is

124 ing plasma levels of TMAO and incident major adverse cardiovascular events (death, myocardial infarct

125 coronary angiography with follow-up of major adverse cardiovascular events (death, myocardial infarct

126 Study end points consisted of major adverse cardiovascular events (death, myocardial infarct

127 omes and Measures: Death, readmission, major adverse cardiovascular events (death, recurrent MI, stro

128 h STR<30% experienced a higher rate of major adverse cardiovascular events (death, reinfarction, isch

129 spitalization for heart failure event, major adverse cardiovascular events (defined as all-cause mort

130 m any cause and a composite outcome of major adverse cardiovascular events, defined as death from any

131 The 30-day coprimary outcomes were major adverse cardiovascular events, defined as death, myocard

132 The rates of major adverse cardiovascular events did not differ significant

133 rdiovascular disease, the incidence of major adverse cardiovascular events did not differ significant

134 ssed the monitoring boundary) only for major adverse cardiovascular events driven by a decrease in re

135 on results in significant reduction in major adverse cardiovascular events driven largely by reductio

136 The cumulative incidence of death or a major adverse cardiovascular event during 17 years after CABG

137 reated with ixmyelocel-T experienced a major adverse cardiovascular event during follow-up when compa

138 ulprit coronary artery, had a 4-fold risk of adverse cardiovascular events during 1-year follow-up.

139 Secondary outcomes included major adverse cardiovascular events (eg, nonfatal myocardial i

140 as associated with a lower rate of the major adverse cardiovascular event end point (HR, 0.68; 95% CI

141 acteristic curve for the prediction of major adverse cardiovascular events, especially in estimated g

142 associated with an increased risk of a major adverse cardiovascular event (hazard ratio for highest v

143 prasugrel and clopidogrel had similar major adverse cardiovascular events (hazard ratio [HR], 0.98;

144 l cutoff value for predicting 12-month major adverse cardiovascular events (hazard ratio [HR]: 2.52,

145 was associated with a lower hazard of major adverse cardiovascular events (hazard ratio, 0.91; 95% c

146 was an independent predictor of 3-year major adverse cardiovascular events (hazard ratio, 1.58; 95% c

147 nin were independently associated with major adverse cardiovascular events (hazard ratio, 2.25; 95% c

148 ficantly associated with occurrence of major adverse cardiovascular events (hazard ratio, 2.4; P=0.00

149 s were associated with an increased risk for adverse cardiovascular events (hazard ratio: 2.3) in the

150 centile) were predictive of subsequent major adverse cardiovascular events (hazard ratio: 2.93, 95% c

151 did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart

152 to 2.97), and 3.09 (0.96 to 8.78) for major adverse cardiovascular events, hospitalizations, and vas

153 eart disease and increased risk of death and adverse cardiovascular events; however, cTnT is rarely d

154 confidence interval [CI], 2.14-2.22), major adverse cardiovascular events (HR, 1.37; 95% CI, 1.34-1.

155 s (HR, 2.04; 95% CI, 1.68-2.49; P<0.001) and adverse cardiovascular events (HR, 1.51; 95% CI, 1.27-1.

156 interval [CI]:1.26 to 1.56; p <0.001), major adverse cardiovascular events (HR: 1.29; 95% CI: 1.16 to

157 total mortality or hospitalization for major adverse cardiovascular events (HR: 7.57; 95% CI: 2.71 to

158 was a composite of first occurrence of major adverse cardiovascular events (ie, cardiovascular death,

159 ies, high sPLA(2)-IIA levels predicted major adverse cardiovascular events in acute coronary syndrome

160 as coronary angiography at predicting future adverse cardiovascular events in advanced chronic kidney

161 assessed the relationship of RCRI with major adverse cardiovascular events in an unselected cohort of

162 de (NO), were designed to reduce the risk of adverse cardiovascular events in diabetic patients.

163 ciated with increased risk of incident major adverse cardiovascular events in humans, and provision o

164 ietary phosphatidylcholine, TMAO levels, and adverse cardiovascular events in humans.

165 tatin for the prevention of stroke and other adverse cardiovascular events in IMPROVE-IT (Improved Re

166 Considering the high risk for major adverse cardiovascular events in patients receiving hemo

167 IgGs are independently associated with major adverse cardiovascular events in patients with myocardia

168 orter 2 inhibitor, reduced the risk of major adverse cardiovascular events in patients with type 2 di

169 the association of PPIs with increased major adverse cardiovascular events in patients with unstable

170 al registries have shown reductions in major adverse cardiovascular events in psoriasis patients and

171 There were 2 adverse cardiovascular events in the metoprolol group an

172 can potentially prevent tens of thousands of adverse cardiovascular events in the over 30% of those w

173 ed with a significantly higher rate of major adverse cardiovascular events in the SA group, p < 0.001

174 use there was a significantly higher rate of adverse cardiovascular events in the testosterone group

175 cizumab had no benefit with respect to major adverse cardiovascular events in the trial involving low

176 isease was an independent predictor of major adverse cardiovascular events in those with type 2 myoca

177 ences in 30-day mortality, in-hospital major adverse cardiovascular events, in-hospital stroke, and i

178 t, with a primary endpoint of a composite of adverse cardiovascular events including myocardial infar

179 Two nonmelanoma skin cancers and two major adverse cardiovascular events, including a fatal stroke,

180 re followed up (median, 2.8 years) for major adverse cardiovascular events, including cardiovascular

181 .0 years) for a composite end point of major adverse cardiovascular events, including cardiovascular

182 refute the association of the Q allele with adverse cardiovascular events independent of clopidogrel

183 minants of severe arteriosclerosis and major adverse cardiovascular events, independent of traditiona

184 ossibly multiple mechanisms underlying these adverse cardiovascular events is critical for evaluating

185 ), the relative risk of stent thrombosis and adverse cardiovascular events is unclear.

186 ember 30, 2011) for the 30-day risk of major adverse cardiovascular events (ischemic stroke, myocardi

187 identified patients at highest risk of major adverse cardiovascular events (log-rank P<0.0001), with

188 severity were related to incidence of major adverse cardiovascular event (MACE) by using Cox proport

189 The primary efficacy endpoint was major adverse cardiovascular events (MACE) (cardiovascular dea

190 Occurrences of major adverse cardiovascular events (MACE) (defined as CV deat

191 h, cardiac transplantation, and MI) or major adverse cardiovascular events (MACE) (hard events and ot

192 VUS) guidance has been shown to reduce major adverse cardiovascular events (MACE) after PCI, principa

193 re (BP) control (<120 mm Hg) had fewer major adverse cardiovascular events (MACE) and deaths but high

194 We performed multivariable model for major adverse cardiovascular events (MACE) and determined the

195 apy was associated with a reduction in major adverse cardiovascular events (MACE) and mortality in th

196 We prospectively studied major adverse cardiovascular events (MACE) at 2 years in 607 p

197 nalyzed for association with death and major adverse cardiovascular events (MACE) at follow-up.

198 xcursion (TAPSE) for the prediction of major adverse cardiovascular events (MACE) defined as the occu

199 ty lipoprotein cholesterol (LDL-C) and major adverse cardiovascular events (MACE) has been observed i

200 guideline-recommended therapies reduce major adverse cardiovascular events (MACE) in patients after m

201 BC) count is associated with increased major adverse cardiovascular events (MACE) in the setting of a

202 nd total atheroma volume with incident major adverse cardiovascular events (MACE) was investigated.

203 Major adverse cardiovascular events (MACE) were defined as the

204 y on the incidence of type 2 diabetes, major adverse cardiovascular events (MACE), and microvascular

205 oronary artery disease (CAD) reporting major adverse cardiovascular events (MACE), consisting of deat

206 lowed up for the composite endpoint of major adverse cardiovascular events (MACE), defined as a compo

207 e risk of both all-cause mortality and major adverse cardiovascular events (MACE), defined as myocard

208 gical procedure, and the occurrence of major adverse cardiovascular events (MACE), including death, m

209 rimary endpoint was the risk of 1-year major adverse cardiovascular events (MACE), which included dea

210 ciation of a family history of AF with major adverse cardiovascular events (MACE).

211 nary imaging actually result in future major adverse cardiovascular events (MACE).

212 owed for incident type 1 and T2MI, and major adverse cardiovascular events (MACE, a composite of all-

213 Outcomes as diabetes, major adverse cardiovascular events (MACE, the composite of my

214 Lifetime major adverse cardiovascular events (MACE: cardiovascular deat

215 -reactive protein (CRP) levels predict major adverse cardiovascular events (MACE: death, myocardial i

216 Risk of major adverse cardiovascular events (MACE; including ischemic

217 infarction and target vessel failure (major adverse cardiovascular events [MACE]).

218 Cardiovascular (major adverse cardiovascular events [MACE], cardiovascular mor

219 were considered: all-cause mortality, major adverse cardiovascular events (MACEs) (including ischemi

220 independent predictors for in-hospital major adverse cardiovascular events (MACEs) and all-cause mort

221 eople, but its association to incident major adverse cardiovascular events (MACEs) and cardiovascular

222 Preliminary reports of major adverse cardiovascular events (MACEs) in psoriasis patie

223 Furthermore, for major adverse cardiovascular events (MACEs), 30-day all-cause

224 points included positive angiography, major adverse cardiovascular events (MACEs), and procedural co

225 een shown to predict the recurrence of major adverse cardiovascular events (MACEs).

226 he ability of CMR and SPECT to predict major adverse cardiovascular events (MACEs).

227 squamous cell carcinomas (SCCs)), and major adverse cardiovascular events (MACEs; five vs. zero even

228 acy outcomes included 1-year composite major adverse cardiovascular events, moderate to severe bleedi

229 ess than 2 mg/L had a 25% reduction in major adverse cardiovascular events (multivariable adjusted ha

230 sis is to compare all-cause mortality, major adverse cardiovascular events, myocardial infarction (MI

231 ary outcomes were all-cause mortality, major adverse cardiovascular events, myocardial infarction, he

232 rding to baseline homoarginine levels: major adverse cardiovascular events (n = 103), cerebrovascular

233 potential benefit of CSL112 to reduce major adverse cardiovascular events needs to be assessed in an

234 espectively (P=0.001), and in-hospital major adverse cardiovascular events occurred in 2.0% versus 8.

235 and 89%, respectively, and in-hospital major adverse cardiovascular events occurred in 31 patients (2

236 No major adverse cardiovascular events occurred in either group.

237 nt percutaneous coronary intervention, major adverse cardiovascular events occurring during follow-up

238 1 of 11,921 (4%), and 257 of 3146 (8%) major adverse cardiovascular events occurring in RCRI classes

239 ansfusion (odds ratio, 0.74; P=0.009), major adverse cardiovascular events (odds ratio, 0.64; P=0.003

240 et adverse clinical events, defined as major adverse cardiovascular events or Bleeding Academic Resea

241 01), but no significant differences in major adverse cardiovascular events or bleeding.

242 n older adults was not associated with fewer adverse cardiovascular events or deaths than hydrochloro

243 patients showed that 27 of 28 patients with adverse cardiovascular events or revascularization had G

244 nce interval [CI], 0.55-1.12; P=0.19), major adverse cardiovascular events (OR, 0.73, CI, 0.51-1.05;

245 nd study their impact on mortality and major adverse cardiovascular event outcomes.

246 C remained an independent predictor of major adverse cardiovascular events (P<0.001) after adjustment

247 rdial damage and an increased risk for major adverse cardiovascular events (P<0.001).

248 with a significantly increased risk of major adverse cardiovascular events, particularly stent thromb

249 Serious adverse cardiovascular events peak in the morning, possi

250 The risk of adverse cardiovascular events peaks in the morning ( app

251 ause the upper bound of the 95% CI for major adverse cardiovascular event plus hospital admission for

252 tive risk reduction in the three-point major adverse cardiovascular event primary outcome (cardiovasc

253 ular diseases was stopped prematurely due to adverse cardiovascular events raising concerns about tes

254 In revascularization patients, the major adverse cardiovascular events rate was not different acr

255 nts, a significant step-up increase in major adverse cardiovascular events rate was observed across t

256 In the gray zone, the major adverse cardiovascular events rate was similar (37 [13.9

257 sociated with significant reduction in major adverse cardiovascular events (rate ratio =0.48; 95% con

258 The major adverse cardiovascular event rates did not differ accord

259 sociated with lower success and higher major adverse cardiovascular event rates in comparison to ante

260 spite this finding, the observed crude major adverse cardiovascular event rates were similar between

261 on on admissions rate, length of stay, major adverse cardiovascular event rates, recidivism rates, an

262 idence interval)=0.79 (0.63, 0.99) for major adverse cardiovascular event rates.

263 4]; P=0.014), resulting in the similar major adverse cardiovascular events rates between the 2 groups

264 hibitors protected against the risk of major adverse cardiovascular events (relative risk 0.84 [95% C

265 essation was associated with increased major adverse cardiovascular event risk.

266 is tested by 4 models confirmed higher major adverse cardiovascular events risk in rs5065 MA carriers

267 Major adverse cardiovascular events risk was not significantly

268 73 [95% CI, 0.59 to 0.90]; P = 0.003), major adverse cardiovascular events (RR, 0.86 [CI, 0.75 to 0.9

269 ntestinal adverse effects, but predispose to adverse cardiovascular events, such as heart failure, my

270 een increased plasma TMAO concentrations and adverse cardiovascular events, such as myocardial infarc

271 Invasive procedures can result in adverse cardiovascular events, such as myocardial infarc

272 no difference in all-cause mortality, major adverse cardiovascular events, target vessel revasculari

273 bstruction (PMO) is more predictive of major adverse cardiovascular events than myocardial infarct (M

274 -0.85] vs 0.55 [0.34-0.90]), while for major adverse cardiovascular events the HR in the group with c

275 dual platelet reactivity are associated with adverse cardiovascular events through independent or int

276 ), to enable subjects at high risk for major adverse cardiovascular events to achieve National Choles

277 linical studies that expand this spectrum of adverse cardiovascular events to include ventricular arr

278 tein [hsCRP], and sPLA(2)-IIA levels), major adverse cardiovascular events (unstable angina, myocardi

279 telet reactivity on clopidogrel treatment on adverse cardiovascular events using a collaborative meta

280 nts: varenicline 11.9%, placebo 11.3%; major adverse cardiovascular events: varenicline 4.0%, placebo

281 Freedom from an adverse cardiovascular event was 92.9+/-1.9% at 25 years

282 The 3-year cumulative rate of major adverse cardiovascular events was 20.4%.

283 aving >/= 1 risk factor) for capturing major adverse cardiovascular events was 59%, 71%, 64%, 66%, an

284 The incidence of both bleeding and adverse cardiovascular events was higher as HAS-BLED sco

285 The rate of major adverse cardiovascular events was not significantly lowe

286 When we examined major adverse cardiovascular events, we found a protective eff

287 Independent predictors for adverse cardiovascular events were age >75 years (HR, 2.

288 placebo on coronary heart disease and major adverse cardiovascular events were assessed over the 4.9

289 At 3 years, major adverse cardiovascular events were not different between

290 Major adverse cardiovascular events were not different from pl

291 acute coronary syndrome, the rates of major adverse cardiovascular events were not increased with th

292 No significant adverse cardiovascular events were noted.

293 The rates of in-hospital major adverse cardiovascular events were significantly lower i

294 ticagrelor can reduce the incidence of major adverse cardiovascular events when administered at hospi

295 er women remained at increased risk of major adverse cardiovascular events, whereas all outcome rates

296 type associated with increased risk of major adverse cardiovascular events while on standard doses of

297 lled trial demonstrated a reduction in major adverse cardiovascular events with CoQ10 supplementation

298 significant reduction in time to first major adverse cardiovascular event) with the GLP-1R agonists l

299 educe rates of major bleeding at 48 h or net adverse cardiovascular events within 30 days compared wi

300 the robotic-assisted procedure without major adverse cardiovascular events within 30 days, and device